[go: up one dir, main page]

IS5550A - 2-(Púrín-9-ýl)-tetrahýdrófúran-3,4-díól afleiður - Google Patents

2-(Púrín-9-ýl)-tetrahýdrófúran-3,4-díól afleiður

Info

Publication number
IS5550A
IS5550A IS5550A IS5550A IS5550A IS 5550 A IS5550 A IS 5550A IS 5550 A IS5550 A IS 5550A IS 5550 A IS5550 A IS 5550A IS 5550 A IS5550 A IS 5550A
Authority
IS
Iceland
Prior art keywords
purin
tetrahydrofuran
diol derivatives
diol
derivatives
Prior art date
Application number
IS5550A
Other languages
English (en)
Inventor
Chan Chuen
Peter Charles Cousins Richard
Cox Brian
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9802066.2A external-priority patent/GB9802066D0/en
Priority claimed from GBGB9813528.8A external-priority patent/GB9813528D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS5550A publication Critical patent/IS5550A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
IS5550A 1998-01-31 2000-06-27 2-(Púrín-9-ýl)-tetrahýdrófúran-3,4-díól afleiður IS5550A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9802066.2A GB9802066D0 (en) 1998-01-31 1998-01-31 Chemical compounds
GBGB9813528.8A GB9813528D0 (en) 1998-06-23 1998-06-23 Chemical compounds
PCT/EP1999/000503 WO1999038877A2 (en) 1998-01-31 1999-01-29 2-(PURIN-9-yl)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES

Publications (1)

Publication Number Publication Date
IS5550A true IS5550A (is) 2000-06-27

Family

ID=26313042

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5550A IS5550A (is) 1998-01-31 2000-06-27 2-(Púrín-9-ýl)-tetrahýdrófúran-3,4-díól afleiður

Country Status (38)

Country Link
US (1) US6762170B1 (is)
EP (1) EP1051425B1 (is)
JP (1) JP2002501928A (is)
KR (1) KR20010034473A (is)
CN (1) CN1289338A (is)
AP (1) AP2000001875A0 (is)
AR (1) AR014508A1 (is)
AT (1) ATE226957T1 (is)
AU (1) AU757183B2 (is)
BG (1) BG63783B1 (is)
BR (1) BR9907270A (is)
CA (1) CA2318278A1 (is)
CO (1) CO4980872A1 (is)
DE (1) DE69903708T2 (is)
DK (1) DK1051425T3 (is)
EA (1) EA003194B1 (is)
EE (1) EE200000441A (is)
ES (1) ES2186330T3 (is)
GE (1) GEP20022839B (is)
HR (1) HRP20000511A2 (is)
HU (1) HUP0101305A3 (is)
ID (1) ID26326A (is)
IL (1) IL137042A0 (is)
IS (1) IS5550A (is)
MA (1) MA26601A1 (is)
NO (1) NO20003867D0 (is)
NZ (1) NZ505452A (is)
OA (1) OA11447A (is)
PE (1) PE20000280A1 (is)
PL (1) PL342670A1 (is)
PT (1) PT1051425E (is)
SI (1) SI1051425T1 (is)
SK (1) SK11192000A3 (is)
SV (1) SV1999000009A (is)
TR (1) TR200002218T2 (is)
TW (1) TW434250B (is)
WO (1) WO1999038877A2 (is)
YU (1) YU44900A (is)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
KR20010071591A (ko) * 1998-06-23 2001-07-28 그레이엄 브레레톤, 레슬리 에드워즈 2-(퓨린-9-일)-테트라히드로푸란-3,4-디올 유도체
GB9813565D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813554D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813540D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
GB0104555D0 (en) * 2001-02-23 2001-04-11 Glaxo Group Ltd New Therapeutic method
GB2372742A (en) 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
US20040162422A1 (en) * 2001-03-20 2004-08-19 Adrian Hall Chemical compounds
AU2002362443B2 (en) 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
GB0206657D0 (en) * 2002-03-21 2002-05-01 Glaxo Group Ltd Novel intermediate and process
GB0206655D0 (en) * 2002-03-21 2002-05-01 Glaxo Group Ltd Novel process
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
WO2005063246A1 (en) * 2003-12-29 2005-07-14 Can-Fite Biopharma Ltd. Method for treatment of multiple sclerosis
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
TWI346109B (en) * 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
US7576069B2 (en) 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
CA2576826C (en) 2004-08-02 2014-09-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
KR101461263B1 (ko) 2005-10-21 2014-11-17 노파르티스 아게 Ｉｌ-13에 대항한 인간 항체 및 치료적 용도
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
PT2013211E (pt) * 2006-04-21 2012-06-21 Novartis Ag Derivados de purina para utilização como agonistas de receptores a2a de adenosina
EP1889846A1 (en) * 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
KR20090073121A (ko) 2006-09-29 2009-07-02 노파르티스 아게 Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘
JP2010508315A (ja) 2006-10-30 2010-03-18 ノバルティス アーゲー 抗炎症剤としてのヘテロ環式化合物
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
PT2391366E (pt) 2009-01-29 2013-02-05 Novartis Ag Benzimidazoles substituídos para o tratamento de astrocitomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EP2464649A1 (en) 2009-08-12 2012-06-20 Novartis AG Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
EP2467141B1 (en) 2009-08-17 2018-10-31 Intellikine, LLC Heterocyclic compounds and uses thereof
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
EP2678338B1 (en) 2011-02-25 2015-09-09 Novartis AG Pyrazolo[1,5-a]pyridines as trk inhibitors
ES2691650T3 (es) 2011-09-15 2018-11-28 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met
HK1203378A1 (en) 2011-11-23 2015-10-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
RU2660354C2 (ru) 2012-04-03 2018-07-05 Новартис Аг Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
HK1219421A1 (zh) 2013-03-15 2017-04-07 因特利凯有限责任公司 激酶抑制剂的组合及其用途
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
CN106414446A (zh) * 2014-03-13 2017-02-15 新加坡科技研究局 基于稠合嘧啶的异羟肟酸盐衍生物
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
BR112017001695A2 (pt) 2014-07-31 2017-11-21 Novartis Ag terapia de combinação
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE768925A (fr) 1970-06-30 1971-11-03 Takeda Chemical Industries Ltd Derives d'adenosine et procede de preparation
US4224438A (en) 1970-07-14 1980-09-23 Boehringer Mannheim Gmbh Adenosine-5'-carboxylic acid amides
DE2034785A1 (de) 1970-07-14 1972-01-20 Boehnnger Mannheim GmbH, 6800 Mann heim Waldhof Adenosin 5 carbonsäurederivate
CA1019727A (en) 1971-03-18 1977-10-25 Abbott Laboratories Adenosine-5'-carboxylic acid amides
BE789773A (fr) 1971-10-08 1973-04-06 Schering Ag Adenosines n6 -substituees et leur procede de
US3864483A (en) 1972-03-22 1975-02-04 Abbott Lab Adenosine-5{40 -carboxylic acid amides
CA1082695A (en) 1972-04-10 1980-07-29 Francis E. Fischer Process for preparing adenosine-5'-carboxamides
US3966917A (en) 1974-07-30 1976-06-29 Abbott Laboratories Platelet aggregation inhibitors
US4146715A (en) 1975-08-27 1979-03-27 Burroughs Wellcome Co. 2-amido-9-(2-acyloxyethoxymethyl)hypoxanthines
DE2621470A1 (de) * 1976-05-14 1977-12-01 Pharma Waldhof Gmbh & Co Nucleosidcarbonsaeurenitrile und ihre derivate, und verfahren zu ihrer herstellung
US4167565A (en) 1976-11-08 1979-09-11 Abbott Laboratories Adenosine-5'-carboxamides and method of use
AU8379182A (en) 1981-06-04 1982-12-09 Procter & Gamble Company, The Composition of salicylates and purine derivatives
JPS58167599A (ja) 1982-03-29 1983-10-03 Tanabe Seiyaku Co Ltd アデノシン誘導体及びその製法
JPS58174322A (ja) 1982-04-07 1983-10-13 Tanabe Seiyaku Co Ltd 線溶促進剤
CA1239397A (en) 1983-08-01 1988-07-19 James A. Bristol N.sup.6-substituted adenosines
DE3406533A1 (de) 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
US4496643A (en) 1984-03-23 1985-01-29 Eastman Kodak Company Two-component dry electrostatic developer composition containing onium charge control agent
DE3576344D1 (de) 1984-04-18 1990-04-12 Whitby Research Inc Cardio-vasodilatatore n-6-substituierte adenosine.
US5310731A (en) 1984-06-28 1994-05-10 Whitby Research, Inc. N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
AU575438B2 (en) 1984-10-26 1988-07-28 Warner-Lambert Company N6 - substituted deoxyribose analogues of adenosines
US4663313A (en) 1984-10-26 1987-05-05 Warner-Lambert Company N6 -tricyclic adenosines for treating hypertension
US5258380A (en) 1985-06-24 1993-11-02 Janssen Pharmaceutica N.V. (4-piperidinylmethyl and -hetero)purines
US4738954A (en) 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4755594A (en) 1986-01-31 1988-07-05 Warner-Lambert Company N6 -substituted adenosines
US5106837A (en) 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
JPH0696534B2 (ja) 1986-04-25 1994-11-30 ヘキストジヤパン株式会社 抗痴呆剤
US4767747A (en) 1986-08-28 1988-08-30 Warner-Lambert Company Method for treating congestive heart failure with N6 -acenaphthyl adenosine
WO1988003148A2 (en) 1986-10-31 1988-05-05 Warner-Lambert Company Heteroaromatic derivatives of adenoside
AU8276187A (en) 1986-10-31 1988-05-25 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
NL8702926A (nl) 1986-12-15 1988-07-01 Sandoz Ag Nieuwe furanuronzuurderivaten en werkwijzen voor het bereiden en toepassen van deze derivaten.
EP0277917A3 (en) * 1987-02-04 1990-03-28 Ciba-Geigy Ag Certain adenosine 5'-carboxamide derivatives
US4968697A (en) 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US4962194A (en) 1987-04-02 1990-10-09 Warner-Lambert Company Method of preparing 51,N6-disubstituted adenosines from inosines
LU87181A1 (fr) 1987-04-06 1988-11-17 Sandoz Sa Nouveaux derives de l'acide furannuronique,leur preparation et leur utilisation comme medicaments
US5219840A (en) 1987-04-06 1993-06-15 Sandoz Ltd. Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
US5021574A (en) 1988-03-03 1991-06-04 Ortho Pharmaceutical Corporation 6-substituted purinyl piperazine derivatives
JPH0725785B2 (ja) 1989-01-11 1995-03-22 日本臓器製薬株式会社 アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
GB8920534D0 (en) 1989-09-11 1989-10-25 Wellcome Found Antiviral compounds
IE903747A1 (en) 1989-10-19 1991-04-24 Searle & Co Method of treating gastrointestinal motility disorders
US5055569A (en) 1989-10-19 1991-10-08 G. D. Searle & Co. N-(6)-substituted adenosine compounds
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
US5140015A (en) 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US5280015A (en) 1990-09-05 1994-01-18 The United States Of America As Represented By The Department Of Health And Human Services 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides
CA2092305C (en) 1990-09-25 2003-02-11 Alfred P. Spada Compounds having antihypertensive and anti-ischemic properties
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
FR2685918B1 (fr) 1992-01-08 1995-06-23 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
FR2687678B1 (fr) 1992-01-31 1995-03-31 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
IT1254915B (it) 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
US5424297A (en) 1992-04-27 1995-06-13 University Of Virginia Alumni Patents Foundation Adenosine dextran conjugates
WO1994002497A1 (en) 1992-07-15 1994-02-03 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Sulfo-derivatives of adenosine
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
WO1994018215A1 (en) 1993-02-03 1994-08-18 Gensia, Inc. Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
WO1995002604A1 (en) 1993-07-13 1995-01-26 The United States Of America, Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists
US5446046A (en) 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
WO1995018817A1 (fr) 1994-01-07 1995-07-13 Laboratoires Upsa Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant
GB9414208D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
AU3255097A (en) 1996-07-05 1998-02-02 Novo Nordisk A/S Novel (n)-alkoxyadenine derivatives acting as cytokine inhibitors
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
WO1998016539A1 (en) 1996-10-14 1998-04-23 Novo Nordisk A/S Novel therapeutically active adenosine derivatives
FR2757518B1 (fr) 1996-12-23 1999-06-11 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
AR017457A1 (es) 1998-02-14 2001-09-05 Glaxo Group Ltd Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias.
KR20010071591A (ko) 1998-06-23 2001-07-28 그레이엄 브레레톤, 레슬리 에드워즈 2-(퓨린-9-일)-테트라히드로푸란-3,4-디올 유도체
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
HRP20000511A2 (en) 2000-12-31
NO20003867L (no) 2000-07-28
TW434250B (en) 2001-05-16
IL137042A0 (en) 2001-06-14
AR014508A1 (es) 2001-02-28
AU757183B2 (en) 2003-02-06
BG63783B1 (bg) 2002-12-29
WO1999038877A3 (en) 1999-09-30
MA26601A1 (fr) 2004-12-20
ES2186330T3 (es) 2003-05-01
NZ505452A (en) 2003-01-31
YU44900A (sh) 2003-01-31
BR9907270A (pt) 2000-10-24
GEP20022839B (en) 2002-11-25
ID26326A (id) 2000-12-14
SI1051425T1 (en) 2003-04-30
CO4980872A1 (es) 2000-11-27
WO1999038877A2 (en) 1999-08-05
EP1051425B1 (en) 2002-10-30
TR200002218T2 (tr) 2000-12-21
BG104729A (en) 2001-04-30
EE200000441A (et) 2001-12-17
NO20003867D0 (no) 2000-07-28
SK11192000A3 (sk) 2001-06-11
CA2318278A1 (en) 1999-08-05
JP2002501928A (ja) 2002-01-22
OA11447A (en) 2004-04-29
CN1289338A (zh) 2001-03-28
ATE226957T1 (de) 2002-11-15
PE20000280A1 (es) 2000-03-28
SV1999000009A (es) 2000-09-05
KR20010034473A (ko) 2001-04-25
DE69903708T2 (de) 2003-07-03
EA003194B1 (ru) 2003-02-27
US6762170B1 (en) 2004-07-13
HUP0101305A3 (en) 2002-08-28
AU2719799A (en) 1999-08-16
EA200000723A1 (ru) 2001-04-23
AP2000001875A0 (en) 2000-09-30
DE69903708D1 (de) 2002-12-05
EP1051425A2 (en) 2000-11-15
PL342670A1 (en) 2001-07-02
DK1051425T3 (da) 2003-03-03
HUP0101305A2 (hu) 2002-04-29
PT1051425E (pt) 2003-03-31
HK1030611A1 (en) 2001-05-11

Similar Documents

Publication Publication Date Title
DE69903708D1 (de) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol-derivate
IS5779A (is) 2-(púrín-9-ýl)-tetrahýdrófúran-3,4-díól afleiður
DK1056759T3 (da) 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol-derivater
NO20006521D0 (no) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol-derivater
DK0948509T3 (da) 2-(Purin-9-yl)-tetrahydrofuran-3,4-diolderivater
SI1056759T1 (en) 2-(purin-9-yl) -tetrahydrofuran-3, 4-diol derivatives
ZA99689B (en) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives.
ZA991154B (en) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives.
HK1033760A (en) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
HK1033761A (en) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
ZA9711535B (en) 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives